Medicxi Ventures Management (Jersey) Ltd

In its 13F for Q1 2026 (holdings as of March 31, 2026, filed April 21, 2026), Medicxi Ventures Management (Jersey) Ltd reported 4 stock positions worth $981.8 million. Its top holding was Centessa Pharmaceuticals (CNTA) at 80.8% of the portfolio, followed by Newamsterdam Pharma (NAMS, 8.7%) and Phathom Pharmaceuticals (PHAT, 8.4%). Compared with Q4 2025, it sold out of 1 and reduced 1. The biggest sale was an exit from Rapt Therapeutics.

Most Recent 13F
Q2 2026
Location
ST. HELIER, Y9
CIK
0001715579
Portfolio Value
$981.8M (Q1 2026)
SEC Filing
0001193125-26-166701 ↗ filed Apr 21, 2026

Holdings Value

0$200.0M$400.0M$600.0M$800.0M$1.0B Q1 2024: $449.2M Q1 2024 Q2 2024: $335.3M Q2 2024 Q3 2024: $528.9M Q3 2024 Q4 2024: $529.0M Q4 2024 Q1 2025: $437.7M Q1 2025 Q2 2025: $427.3M Q2 2025 Q3 2025: $744.4M Q3 2025 Q4 2025: $835.0M Q4 2025 Q1 2026: $981.8M $981.8M Q1 2026 Q2 2026: $177.4M Q2 2026

Holdings 4 stocks · $981.8M
CNTA Centessa Pharmaceuticals Ltd. 80.76% 19,963,157 $792.9M No change
NAMS Newamsterdam Pharma Co. NV 8.72% 2,674,182 $85.6M Reduce -6.8%
PHAT Phathom Pharmaceuticals Inc. 8.45% 7,464,572 $82.9M No change
AURA Aura Biosciences Inc. 2.07% 3,039,892 $20.3M No change

Portfolio Sells Q4 2025 → Q1 2026
RAPT THERAPEUTICS INC Sold out 0.00% −11.33
NAMS Newamsterdam Pharma Co. NV Reduce -6.8% 8.72% −3.34

Portfolio Buys Q4 2025 → Q1 2026
None this quarter.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 3$177.4MPHAT, NAMS, AURA
Q1 2026 4$981.8MCNTA, NAMS, PHAT, AURA
Q4 2025 5$835.0MCNTA, PHAT, NAMS, RAPT THERAPEUTICS INC, AURA
Q3 2025 5$744.4MCNTA, PHAT, NAMS, RAPT THERAPEUTICS INC, AURA
Q2 2025 5$427.3MCNTA, PHAT, NAMS, RAPT, AURA
Q1 2025 5$437.7MCNTA, NAMS, PHAT, RAPT THERAPEUTICS INC, AURA
Q4 2024 5$529.0MCNTA, NAMS, PHAT, RAPT THERAPEUTICS INC, AURA
Q3 2024 4$528.9MCNTA, PHAT, NAMS, AURA
Q2 2024 4$335.3MCNTA, PHAT, NAMS, AURA
Q1 2024 5$449.2MCNTA, PHAT, NAMS, MRUS, AURA